ARTES, a company specialising in the development and transfer of recombinant cell lines and protein production processes from microbial expression systems, and Basic Pharma, a pharmaceutical company focusing on pharmaceutical products, have made significant progress in their strategic collaboration to produce recombinant Human Serum Albumin derived from Hansenula yeast.
The teams have been working successfully on the development of rHSA and the project is on track to completion.
The companies are expected to release the first vials containing rHSA this Summer, as the project approaches the final stages of development. The target audience for the rHSA includes laboratories in academia and industry that require small quantities of high-quality recombinant proteins for their research endeavors.
Michael Piontek, Managing Director of ARTES Biotechnology, added: “The combination of development and manufacturing capabilities at both ARTES and our partner Basic Pharma enables the launch of human albumin today and several new peptides and proteins in the near future.”
Ralph Bosmans, Manager of Biotechnology at Basic Pharma, expressed his satisfaction with the progress: "This collaboration has been instrumental in realizing our vision of offering reagents for research applications. Our joint efforts with ARTES have paved the way for the release of Human Serum Albumin, marking a significant milestone in our strategic collaboration."
ARTES and Basic Pharma near completion of their joint rHSA project
The collaborative project involved the production of recombinant human serum albumin (rHSA)
You may also like
Trending Articles
You may also like
Manufacturing
![SCHOTT Pharma launches EVERIC lyo & amber vials for light-sensitive ADCs]()
SCHOTT Pharma launches EVERIC lyo & amber vials for light-sensitive ADCs
Featuring the well-known EVERIC® lyo coating, EVERIC® lyo & amber is designed for lyophilised, light-sensitive antibody-drug-conjugates (ADCs). It offers reliable light protection at the primary packaging level, already during the fill-and-finish process. EVERIC amber is the first specialty vial for highly light-sensitive medications that simultaneously meets regulatory light transmission requirements in the EU, the U.S., and Japan
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
![Portable gas detection in the pharmaceutical sector]()
Portable gas detection in the pharmaceutical sector
Gas safety is a critical consideration in the pharmaceutical sector. Hazardous gases and airborne contaminants are common by-products of manufacturing processes … and employers must control worker exposure in accordance with relevant legislation and industry standards
Manufacturing
![New legal duties for QPs in decentralised manufacturing]()
New legal duties for QPs in decentralised manufacturing
In this clip, Dr. Peter Gough explains that QPs will be responsible for supervising decentralised activities, conducting regular audits, carrying out periodic on-site visits, confirming GMP compliance to regulatory authorities and notifying changes that may affect quality or safety
Manufacturing
![FDA escalates action against Dabur India over systemic data-integrity and cGMP failures]()
FDA escalates action against Dabur India over systemic data-integrity and cGMP failures
The US FDA has issued a warning letter to Dabur India following an inspection that identified falsified records, missing laboratory data, inadequate cleaning and process validation and weaknesses in quality-unit oversight, saying the company's response failed to address the systemic nature of the deficiencies
Manufacturing
![DNA Script and GE Healthcare awarded $26m ARPA-H funding to scale cell-free DNA bioproduction]()
DNA Script and GE Healthcare awarded $26m ARPA-H funding to scale cell-free DNA bioproduction
The pair will combine DNA Script's EDS technology with GE HealthCare's DNA scaling technology to create a faster, more flexible manufacturing process for cell-free DNA as the use of personalised and time-sensitive genetic medicines grows